Integrated Use of Minimal Residual Disease Classification and IKZF1 Alteration Status Accurately Predicts 79% of Relapses In Pediatric Acute Lymphoblastic Leukemia

被引：0
|
作者：
Waanders, Esme [1 ]
van der Velden, Vincent H. J. [2 ]
van der Schoot, Ellen [3 ,4 ]
van Leeuwen, Frank N.
van Reijmersdal, Simon V. [1 ]
de Haas, Valerie [5 ]
Veerman, Anjo J. [6 ]
van Kessel, Ad Geurts [1 ]
Hoogerbrugge, Peter M.
Kuiper, Roland P. [1 ]
van Dongen, Jacques J. M. [2 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands
[2] Erasmus Univ, Dept Immunol, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands
[3] Sanquin Res, Expt Immunohematol, Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
[5] DCOG, The Hague, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Paediat Oncol, Amsterdam, Netherlands
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [1] Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
    Waanders, E.
    van der Velden, V. H. J.
    van der Schoot, C. E.
    van Leeuwen, F. N.
    van Reijmersdal, S. V.
    de Haas, V.
    Veerman, A. J.
    van Kessel, A. Geurts
    Hoogerbrugge, P. M.
    Kuiper, R. P.
    van Dongen, J. J. M.
    LEUKEMIA, 2011, 25 (02) : 254 - 258
  • [2] Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
    E Waanders
    V H J van der Velden
    C E van der Schoot
    F N van Leeuwen
    S V van Reijmersdal
    V de Haas
    A J Veerman
    A Geurts van Kessel
    P M Hoogerbrugge
    R P Kuiper
    J J M van Dongen
    Leukemia, 2011, 25 : 254 - 258
  • [3] Impact of IKZF1 Deletions and IKZF1 Plus in Pediatric Acute Lymphoblastic Leukemia Outcome
    Sara Felice, Maria
    Laura Rubio, Patricia
    Ruth Guitter, Myriam
    Gabriel Rossi, Jorge
    Alberto Digiorge, Jorge
    Constanza Guardia, Maria
    Fernandez Barbieri, Maria Angelica
    Gutierrez, Gladys
    Recondo, Ezequiel
    Vides Herrera, Maria Soledad
    Livio, Vanina
    Noemi Alonso, Cristina
    BLOOD, 2018, 132
  • [4] IKZF1 as a novel marker of minimal residual disease in patients with acute lymphoblastic leukaemia
    Barkhatov, M.
    Lebedinova, N.
    Zagrivnaya, M.
    Semenova, E.
    Zubarovskaya, L.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S247 - S248
  • [5] Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia
    Lana, T.
    de Lorenzo, P.
    Bresolin, S.
    Bronzini, I.
    den Boer, M. L.
    Cave, H.
    Fronkova, E.
    Stanulla, M.
    Zaliova, M.
    Harrison, C. J.
    de Groot, H.
    Valsecchi, M. G.
    Biondi, A.
    Basso, G.
    Cazzaniga, G.
    te Kronnie, G.
    LEUKEMIA, 2015, 29 (10) : 2107 - 2110
  • [6] Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia
    T Lana
    P de Lorenzo
    S Bresolin
    I Bronzini
    M L den Boer
    H Cavé
    E Froňková
    M Stanulla
    M Zaliova
    C J Harrison
    H de Groot
    M G Valsecchi
    A Biondi
    G Basso
    G Cazzaniga
    G te Kronnie
    Leukemia, 2015, 29 : 2107 - 2110
  • [7] Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
    Lana, Tobia
    de Lorenzo, Paola
    Bresolin, Silvia
    Bronzini, Ilaria
    Den Boer, Monique L.
    Cave, Helene
    Fronkova, Eva
    Stanulla, Martin
    Zaliova, Marketa
    Harrison, Christine J.
    de Groot-Kruseman, Hester
    Schwab, Claire
    Valsecchi, Maria Grazia
    Biondi, Andrea
    Basso, Giuseppe
    Cazzaniga, Giovanni
    te Kronnie, Geertruy
    BLOOD, 2014, 124 (21)
  • [8] Prognostic significance of IKZF1 alteration status in pediatric B-lineage acute lymphoblastic leukemia: a meta-analysis
    Feng, Jianhua
    Tang, Yongmin
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 889 - 891
  • [9] Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease Study in pediatric acute lymphoblastic leukemia: a Children's Oncology Group
    Chen, I. Ming
    Harvey, Richard C.
    Mullighan, Charles G.
    Gastier-Foster, Julie
    Wharton, Walker
    Kang, Huining
    Borowitz, Michael J.
    Camitta, Bruce M.
    Carroll, Andrew J.
    Devidas, Meenakshi
    Pullen, D. Jeanette
    Payne-Turner, Debbie
    Taisan, Sarah K.
    Reshmi, Shalini
    Cottrell, Catherine E.
    Reaman, Gregory H.
    Bowman, W. Paul
    Carroll, William L.
    Loh, Mignon L.
    Winick, Naomi J.
    Hunger, Stephen P.
    Willman, Cheryl L.
    BLOOD, 2012, 119 (15) : 3512 - 3522
  • [10] Are the Minimal Residual Disease Status and IKZF1 Mutations Play Prognostic Role in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Treated by RALL Protocols?
    Gavrilina, Olga
    Baskhaev, Galina
    Biderman, Bella
    Zarubina, Ksenia
    Troitskaya, Vera
    Sudarikov, Andrey
    Julhakyan, Hunan
    Parovichnikova, Elena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S268 - S268
12345